IDH3A and glioblastoma: The World Health Organization (WHO) initially classified GBM according to isocitrate dehydrogenase (IDH) mutation status in their “2016 Classification of Brain Tumors”, which was subsequently refined in 2021 to incorporate more comprehensive molecular and genetic characteristics [4].